| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Crescent Biopharma, Inc.
13G/A
Amendment 1
CBIO · 38000Q201
|
10.3% |
10/14/2025
Event 10/7/2025
|
|||
| 1Globe Capital LLC | 10.3% | ||||
| Jiaqiang Li | 10.3% | ||||
|
Sinovac Biotech Ltd
13D/A
Amendment 7
SVA · P8696W104
|
32.3% |
9/12/2025
Event 9/10/2025
|
|||
| 1Globe Capital LLC | 32.3% | ||||
| 1Globe Biomedical (Hong Kong) Company Limited | 32.3% | ||||
| Jiaqiang Li | 32.3% | ||||
|
Crescent Biopharma, Inc.
13G
CBIO · 38000Q201
|
6.5% |
8/20/2025
Event 8/13/2025
|
|||
| 1Globe Capital LLC | 6.5% | ||||
| Jiaqiang Li | 6.5% | ||||
|
Sinovac Biotech Ltd
13D/A
Amendment 6
SVA · P8696W104
|
32.3% |
7/7/2025
Event 7/7/2025
|
|||
| 1Globe Capital LLC | 32.3% | ||||
| 1Globe Biomedical (Hong Kong) Company Limited | 32.3% | ||||
|
Sinovac Biotech Ltd
13D/A
Amendment 5
SVA · P8696W104
|
32.3% |
7/3/2025
Event 6/27/2025
|
|||
| 1Globe Capital LLC | 32.3% | ||||
| 1Globe Biomedical (Hong Kong) Company Limited | 32.3% | ||||
|
Sinovac Biotech Ltd
13D/A
Amendment 4
SVA · P8696W104
|
32.3% |
7/1/2025
Event 6/27/2025
|
|||
| 1Globe Capital LLC | 32.3% | ||||
| 1Globe Biomedical (Hong Kong) Company Limited | 32.3% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.